JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Johnson & Johnson (NYSE:JNJ) Stock

Johnson & Johnson (NYSE:JNJ) had its price target raised by research analysts at JPMorgan Chase & Co. from $270.00 to $285.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 5.51% from the company’s previous close.

JNJ has been the topic of a number of other research reports. Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a research report on Wednesday, July 15th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. HSBC upped their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Morgan Stanley increased their target price on Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $275.87.

Johnson & Johnson Trading Down 0.7%

Shares of JNJ opened at $270.12 on Tuesday. The firm has a market capitalization of $650.97 billion, a price-to-earnings ratio of 31.43, a PEG ratio of 2.59 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. Johnson & Johnson has a 1-year low of $181.07 and a 1-year high of $281.07. The company has a 50-day moving average of $265.99 and a 200 day moving average of $247.86.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the prior year, the firm earned $2.77 EPS. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts expect that Johnson & Johnson will post 11.61 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is currently owned by company insiders.

Institutional Trading of Johnson & Johnson

Institutional investors have recently bought and sold shares of the stock. National Pension Service grew its stake in Johnson & Johnson by 1.3% during the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company’s stock worth $1,327,493,000 after purchasing an additional 67,484 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Johnson & Johnson by 8.8% in the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after buying an additional 3,133 shares during the period. Elefante Mark B increased its stake in shares of Johnson & Johnson by 9.8% during the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after buying an additional 2,563 shares during the period. Signal Advisors Wealth LLC raised its holdings in Johnson & Johnson by 76.1% in the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock valued at $3,697,000 after acquiring an additional 6,539 shares in the last quarter. Finally, Gradient Investments LLC increased its holdings in shares of Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after acquiring an additional 13,737 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New IMAAVY (nipocalimab) data showed sustained disease control through two years, improved daily function and muscle strength, and reduced corticosteroid use in certain generalized myasthenia gravis patients. The findings support IMAAVY’s potential as a growth product. Johnson & Johnson IMAAVY data
• Positive Sentiment: Recent clinical progress for Tremfya in psoriatic arthritis and Caplyta in bipolar mania is strengthening the case that JNJ can build a post-Stelara growth portfolio. Caplyta is particularly important following JNJ’s $14.6 billion acquisition of Intra-Cellular Therapies. JNJ post-Stelara growth story
• Positive Sentiment: JNJ’s long record of dividend increases and more than $85 billion in cumulative shareholder distributions continue to appeal to income-focused investors, supporting the stock’s defensive appeal. JNJ cash returns
• Neutral Sentiment: Analysts expect third-quarter 2026 earnings to show single-digit bottom-line growth. The report, due next month, could become the next major catalyst as investors assess whether newer products can offset pressure elsewhere in the portfolio. JNJ Q3 2026 earnings expectations
• Negative Sentiment: After a strong multiyear rally, valuation has become a concern. One analyst continues to rate JNJ Hold despite identifying catalysts, while the reported consensus target of $274.13 offers limited upside relative to the current trading level. JNJ analyst hold view
• Negative Sentiment: Investors remain concerned that declining sales from a major blockbuster drug and ongoing litigation costs could offset gains from JNJ’s oncology, immunology and neuroscience pipeline. JNJ growth and litigation risks

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.